AstraZeneca invests in AI-led research agreement with China's CSPC, up to US$5.3 billion
.png)
Anglo-Swedish pharmaceutical giant AstraZeneca announced they have signed a deal with China’s CSPC Pharmaceutical Group worth up to US$5.3 billion to drive AI-led research development of therapies for chronic conditions.
This deal marks AstraZeneca’s increased business presence in China, the company’s second-largest market, despite challenges faced regarding the arrest of AstraZeneca’s China president and facing import-related fines. Under the deal, AstraZeneca and CSPC will work together for the discovery and development of preclinical small molecule oral therapy drug candidates for immunological diseases, among other preclinical candidates. CSPS will be conducting their AI-driven research in the city of Shijiazhuang.
AstraZeneca previously announced business activity in China in March of this year, investing US$2.5 billion in a new R&D hub in Beijing, detailing a 5-year strategic partnership with the Beijing Municipal Government and the Beijing Economic Technological Development Area office, as well as partnerships with three China-based biotechs. The pharmaceutical company’s portfolio already includes a state-of-the-art Shanghai R&D centre utilising AI and data science laboratories for early-stage research and clinical development.
An upfront investment of US$110 million will be paid to CSPC, with eligibility for CSPC to receive up to US$1.62 billion when achieving development and sales-related milestones. CSPC boasts a wide-ranging pipeline with portfolios in cancer treatments and therapies for cardiovascular diseases. 80% of CSPC’s total revenue derives from its finished drug portfolio. The agreement between the Chinese firm and AstraZeneca includes rights for AstraZeneca to enable options for exclusive licenses for candidates identified during the R&D collaboration.
Source:
AstraZeneca signs AI research deal with China’s CSPC for chronic diseases [Accessed June 16, 2025] https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-agrees-research-deal-worth-up-522-billion-with-cspc-2025-06-13/
Related News
-
News CPHI Americas 2025 - From the Floor
Our From the Floor live blog is back in Philadelphia for this year’s CPHI, this time under the new name CPHI Americas to embrace and represent the whole of the pharmaceutical supply chain from north to south.
-
News Women in Pharma: Unlocking patient inclusion at CPHI Americas
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can towards making the healthcare industry and workplace more equitable and inclusive.&nbs... -
News Tracking Innovation with Thermo Fisher Scientific: CPHI Americas Track Sponsor interview
As we gear up for CPHI Americas from May 20-22, 2025 at the Philadelphia Convention Center, we sat down with Track Sponsor Thermo Fisher Scientific to discuss the future of bioproduction in pharma.
-
News PhRMA trade association issues comments on Section 232 investigation
The Pharmaceutical Research and Manufacturers of America (PhRMA), an American trade association representing groups in the pharmaceutical industry, issued a letter on May 6, 2026 to the Department of Commerce regarding the Section 232 National Security... -
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News Executive order to elevate US pharma manufacturing signed by Trump
On Monday, May 5, US President Trump signed an executive order to reduce regulatory barriers for domestic US pharmaceutical manufacturing, including key ingredients and materials for manufacturing prescription drugs.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News China import tax fine could cost AstraZeneca up to US$8 million
British-Swedish drugmaker AstraZeneca could find itself facing fines of up to US$8million in China due to suspected unpaid import taxes on breast cancer drug Enhertu.